Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5004 in type 2 diabetes mellitus
NCT06579105Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of elecoglipron in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Oct 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06579105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579105.